Edwards Lifesciences - EW Stock Forecast, Price & News

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings or view top-rated stocks.

19 equities research analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $134.00. On average, they expect the company's share price to reach $89.74 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 10.1% and is now trading at $82.12.
View the best growth stocks for 2023 here.

Edwards Lifesciences saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 13,930,000 shares, a decrease of 9.2% from the December 31st total of 15,340,000 shares. Based on an average daily volume of 5,170,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 2.3% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Tuesday, January, 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.03. The medical research company earned $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 26.05% and a net margin of 28.27%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.51 EPS.
Read the conference call transcript.

Edwards Lifesciences's stock split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.45-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (1.24%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), DekaBank Deutsche Girozentrale (0.24%), New York State Common Retirement Fund (0.20%), Bank of Montreal Can (0.20%) and CCLA Investment Management (0.17%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $82.12.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $50.77 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.44 on an earnings per share basis.

The company employs 15,700 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.